Ocrevus, Rituximab Linked to More Severe COVID-19 Cases in Italy.
From; Multiple Sclerosis News Today ; APRIL 27, 2021 ; IN AAN 2021, NEWS.
Disease-modifying therapies (DMTs) that target CD20 are associated with worse outcomes from COVID-19 in multiple sclerosis (MS) patients, an analysis of patient data from Italy suggests.
Conversely, interferon-based DMTs and Aubagio (teriflunomide) were associated with less severe COVID-19 cases in the analysis.
These findings were shared in the presentation, “Different disease modifying therapies can increase or decrease Covid-19 severity in Multiple Sclerosis,” at the 2021 annual meeting of the American Academy of Neurology (AAN).
——————————————————-
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Posted By;
Nigel Caswell